Retrospective Comparison of External Beam Radiotherapy and Radical Prostatectomy in High-Risk, Clinically Localized Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 4, 2009, Pages 975-982

  Arcangeli, Giorgio ^a   Strigari, Lidia ^a   Arcangeli, Stefano ^a   Petrongari, Maria Grazia ^a   Saracino, Biancamaria ^a   Gomellini, Sara ^a   Papalia, Rocco ^a   Simone, Giuseppe ^a   De Carli, Piero ^a   Gallucci, Michele ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

External beam radiotherapy; Freedom from biochemical failure; High risk disease; Prostate tumors; Radical prostatectomy

Indexed keywords

EXTERNAL BEAM RADIOTHERAPY; FREEDOM FROM BIOCHEMICAL FAILURE; FREEDOM FROM BIOCHEMICAL FAILURES; HIGH-RISK DISEASE; PROSTATE TUMOR; RADICAL PROSTATECTOMY;

ANTIGENS; DECISION MAKING; DOSIMETRY; FLUORINE CONTAINING POLYMERS; MULTIVARIANT ANALYSIS; ONCOLOGY; QUALITY ASSURANCE; RADIOTHERAPY; TUMORS;

RISK ANALYSIS;

GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN;

ADJUVANT THERAPY; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANTIGEN DETECTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; THERAPY EFFECT; TREATMENT FAILURE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; ITALY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROSTATE TUMOR; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; ROME; TREATMENT OUTCOME;

EID: 70449709856     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.12.045     Document Type: Article

References (28)

1. Barry M.J., Fleming C., Coley C.M., et al. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer?. Urology 46 (1995) 2-13
2. Surveillance, Epidemiology, and End Results Program. Case diagnosed in 1973-1992, public-use database (1995), National Cancer Institute, Bethesda
3. Bagshaw M.A., Cox R.S., and Hancock S.L. Control of prostate cancer with radiotherapy: Long-term results. J Urol 152 (1994) 1781-1785
4. Wasson J., Cushman C., Bruskewitz R., et al. A structured literature review of treatment for localized prostate cancer. Arch Family Med 2 (1993) 487-493
5. National Comprehensive Cancer Center Network. NCCN clinical practice guideline in oncology: Prostate cancer, V.I.2007. Available from: www.nccn.org/professionals/physician_gls/PDF/prostate.pdf.
6. In: Sobin L.H., and Wittekind C. (Eds). TNM classification of malignant tumors, 6th ed (2002), Wiley-Liss, New York
7. Gleason D.F. Classification of prostate carcinomas. Cancer Chemother Rep 50 (1966) 125-128
8. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
9. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
10. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 53 (1958) 457-481
11. Cox D.R. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
12. Kalbfleisch J.D., and Prentice R.L. Statistical analysis of failure time data (1980), Wiley, New York p. 163-178
13. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer: Vol 1. Worldwide evidence 1985-1990 (1990), Oxford University Press, Oxford, United Kingdom
14. Oefelein M.G., Grayhack J.T., and McVary K.T. Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate. Cancer 76 (1995) 2535-2542
15. Lu-Yao G.L., and Yao S.L. Population based study of long term survival in patients with clinically localized prostate cancer. Lancet 349 (1997) 906-910
16. Kupelian P., Katcher J., Levin H., et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1-T2 prostate cancer: Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am 3 (1997) 78-87
17. Akakura K., Suzuki H., Ichikawa T., et al. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: Results at median follow-up of 102 months. Jpn J Clin Oncol 36 (2006) 789-793
18. Tewari A., Divine G., Chang P., et al. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy-a propensity scoring approach. J Urol 177 (2007) 911-915
19. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1102
20. Zietman A.L., De Silvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 294 (2005) 1233-1239
21. Kupelian P., Elshaikh M., Reddy C.A., et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 20 (2002) 3376-3385
22. D'Amico A.V., Whittington R., Kaplan I., et al. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of >4-20 ng/mL. Int J Radiat Oncol Biol Phys 37 (1997) 1053-1058
23. Do T.M., Parker R.G., Smith R.B., et al. High-grade carcinoma of the prostate: A comparison of current local therapies. Urology 57 (2001) 1121-1127
24. Cozzarini C., Bolognesi A., Ceresoli G.L., et al. Role of postoperative radiotherapy after lymphadenectomy and radical retropubic prostatectomy: A single institute experience of 415 patients. Int J Radiat Oncol Biol Phys 59 (2004) 674-683
25. Bolla M., Van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: A randomized controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
26. Martinez A.A., Demanes D.J., Galalac R., et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regimen. Int J Radiat Oncol Biol Phys 62 (2005) 1322-1331
27. Zapatero A., Valcárcel F., Calvo F.A., et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol 23 (2005) 6561-6568
28. Kupelian P., Buchsbaum J., Patel C., et al. Impact of biochemical failure as a predictor of overall survival in men with localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 52 (2002) 704-711